Revisiting Phase III Clinical Trials for Antimalarial Drugs
Author Information
Author(s): Steffen Borrmann, Tim Peto, Robert W. Snow, Win Gutteridge, Nicholas J. White
Primary Institution: Kenya Medical Research Institute/Wellcome Trust Research Programme
Hypothesis
What are the appropriate endpoints and their measurement during phase III trials of new antimalarial drugs?
Conclusion
The study emphasizes the need for a new approach in assessing antimalarial drugs during clinical development to ensure effective public health deployment.
Supporting Evidence
- Curing malaria episodes is the key priority for antimalarial treatment.
- The delay of secondary malaria episodes by slowly eliminated new drugs provides additional public health benefits.
- WHO suggests aiming to achieve parasitological cure rates of ≥95%; if adopted for drug development this sets a high bar.
- Small differences in cure rates of ≥95% may be outweighed by advantages in cost, dosing, or tolerability.
Takeaway
This study talks about how we should check if new malaria medicines work well and how to measure their success, especially in places where malaria is common.
Methodology
The paper reflects on the design and interpretation of phase III trials for antimalarial drugs.
Potential Biases
There are risks of misclassification of recurrent infections which can affect the accuracy of cure rate estimates.
Limitations
The study highlights the complexity of measuring drug efficacy due to inter-population variations and the challenges in distinguishing between recrudescence and reinfection.
Participant Demographics
The study discusses the impact of age and immunity on malaria treatment outcomes, particularly in children.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website